Technology And Equipment Tenders

Open House Original Discount Contracts 2025-19 - Tafamidis

Completion not Excl. Pharmaceutical Discount Club. According to Section 130A (8) Sgb V by an Open House Model to the Active Ingredient Formoterol/Glycopyrronium/Budesonide (Atc Code According to Who: R03al11)

Open-House Drug Discount Contracts in Accordance with Section 130A (8C) Sgb V Bevacizumab, Atc L01fg01-Contract Regions of Lower Saxony, Bremen and Saxony-Anhalt

Open-House Drug Discount Contracts in Accordance with Section 130A (8C) Sgb V Trastuzumab, Atc L01fd01-Contract Regions of Lower Saxony, Bremen and Saxony-Anhalt

Open-House Drug Discount Contracts in Accordance with Section 130A (8C) Sgb V Rituximab, Atc L01fa01-Contract Regions of Lower Saxony, Bremen and Saxony-Anhalt

V315_2025 - Wi-Aos - Xuv-Monochromator Prototyp (Sx-700)

Completion of a Non -Exclusive Discount Agreement According to Section 130A (8) Sgb V on the Active Ingredient Benralizumab, Atc R03dx10 for the Time 01.06.2025 - 31.2027

Completion of a Non -Exclusive Discount Agreement According to Section 130A (8) Sgb V on the Active Ingredient Formoterol + Glycopyrronium + Budesonide, Atc R03al11 for the Time 01.06.2025 - 31.20227

Completion of a Non -Exclusive Discount Agreement According to Section 130A (8) Sgb V on the Active Ingredient Tezepelumab, Atc R03dx11 for the Time 01.06.2025 - 31.2027

Open House Biologika Discount Treaties 2025-10 - Choriongonadotropin Alfa